AG
CTMX icon

Algert Global’s CytomX Therapeutics CTMX Stock Holding History

Algert Global’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,570
Closed -$35K – 1205
2024
Q4 		$35K Buy
+33,570
New +$36.1K ﹤0.01% 1147
2022
Q3 		– Sell
-30,340
Closed -$56K – 1200
2022
Q2 		$56K Buy
+30,340
New +$58.1K ﹤0.01% 1147
2020
Q1 		– Sell
-32,403
Closed -$269K – 428
2019
Q4 		$269K Buy
32,403
+11,560
+55% +$78K 0.08% 276
2019
Q3 		$154K Sell
20,843
-28,280
-58% -$279K 0.06% 298
2019
Q2 		$551K Buy
+49,123
New +$515K 0.2% 159
2019
Q1 		– Sell
-75,586
Closed -$1.14M – 332
2018
Q4 		$1.14M Buy
75,586
+8,777
+13% +$130K 0.32% 111
2018
Q3 		$1.24M Buy
66,809
+45,159
+209% +$1.03M 0.27% 141
2018
Q2 		$495K Buy
21,650
+350
+2% +$8.94K 0.1% 244
2018
Q1 		$606K Sell
21,300
-29,933
-58% -$854K 0.12% 233
2017
Q4 		$1.08M Buy
51,233
+5,380
+12% +$112K 0.26% 158
2017
Q3 		$833K Buy
45,853
+11,050
+32% +$172K 0.19% 183
2017
Q2 		$539K Buy
+34,803
New +$525K 0.15% 213

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Algert Global's CTMX Position: Q1 2025 in Review

Algert Global sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 33,570 shares — an estimated $35K sold.

Algert Global first reported a position in CTMX in Q2 2017 and held it in 12 quarters. The position peaked at $1.24M in Q3 2018. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Algert Global reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Algert Global sold 33,570 CytomX Therapeutics shares in Q1 2025, an estimated $35K.
  • Algert Global first reported a position in CytomX Therapeutics in Q2 2017 and held it in 12 quarters.
  • Algert Global's CytomX Therapeutics position peaked at $1.24M in Q3 2018.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.